Novartis AG is looking at ways of turning around the fortunes of the US operations at its Sandoz division but the option of selling off its generic pills business across the Atlantic, which a Reuters report claims is under consideration, has raised eyebrows among observers.
The news agency, citing unnamed sources who are familiar with the matter, reported that a sale process for the unit...








